Every 10-Q that Nutriband Inc. (NTRB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NTRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTRB filings page.
NutriBand Inc. (NTRB) reported lower revenue but narrower losses for the three and six months ended July 31, 2026. Revenue for the quarter was $437,514 versus $622,452 a year earlier, and six‑month revenue was $870,913 versus $1,289,884, primarily reflecting reduced sales at Pocono Pharmaceuticals after a principal customer moved operations to Asia.
Six‑month net loss improved to $2,122,517 from $3,389,206, helped by lower selling, general and administrative expenses and reduced research and development spending on the AVERSA Fentanyl program. Operating cash outflow fell to $1,148,103, and cash stood at $3,421,615 with working capital of $2,912,335, which management believes is sufficient to support operations for at least one year and alleviates prior going‑concern uncertainty. The company continues to invest in its AVERSA abuse‑deterrent transdermal pipeline and maintains a material weakness in internal control over financial reporting, despite some remediation efforts.
Nutriband Inc. reported modest revenue growth but significantly higher losses for the quarter and nine months ended October 31, 2025. Revenue for the quarter fell to $346,058 from $645,796, while nine‑month revenue rose to $1.64M from $1.50M, all from its Pocono Pharmaceuticals manufacturing segment.
Despite a nine‑month gross profit of $477,367, heavy selling, general and administrative costs of $6.07M and research and development spending of $1.70M on the AVERSA Fentanyl program drove a nine‑month net loss of $7.26M. A non‑cash preferred stock dividend valued at $21.81M pushed the net loss available to common stockholders to $29.08M, or ($2.54) per share.
Nutriband ended the period with cash of $5.31M and working capital of $5.04M, supported by prior equity financing and warrant exercises. Management’s forecasts lead them to conclude that earlier substantial doubt about continuing as a going concern is alleviated. The company continues development of its AVERSA abuse‑deterrent transdermal products with partner Kindeva and has outstanding warrants and stock options that could further affect its capital structure.